Form 4: Avalo Therapeutics CMO Reports Net Stock Increase

Avalo Therapeutics' Chief Medical Officer, Mittie Doyle, reported a disposition of 1,013 common shares for tax purposes, alongside a net increase in beneficial ownership to 3,622 shares, including those from an Employee Stock Purchase Plan.

Summary

• Mittie Doyle, Chief Medical Officer of Avalo Therapeutics, Inc. (AVTX), reported transactions on December 10, 2025.
• Doyle disposed of 1,013 shares of Avalo Therapeutics common stock at a price of $4.10 per share.
• This disposition was made under transaction code 'F', typically indicating a sale to cover tax withholding obligations related to equity awards.
• Concurrently, Doyle acquired 3,622 shares through the Issuer's Employee Stock Purchase Plan.
• Following these reported transactions, Doyle's total beneficial ownership of Avalo Therapeutics common stock is 3,622 shares, representing a net increase in holdings.

Sentiment

Score: 6

Explanation: The transaction is largely routine, involving a disposition for tax purposes, but the overall beneficial ownership increased due to ESPP acquisition, indicating continued insider confidence.

Positives

• Mittie Doyle's beneficial ownership of Avalo Therapeutics common stock increased by a net of 2,609 shares (3,622 acquired via ESPP minus 1,013 disposed for tax), demonstrating continued investment and confidence in the company.
• The acquisition of 3,622 shares through the Employee Stock Purchase Plan indicates active participation in the company's equity programs by a key executive.

Negatives

• A disposition of 1,013 shares of common stock occurred, which, even if for tax withholding, reduces the direct holdings from a prior amount.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency on insider holdings and routine equity transactions, showing a net increase in executive ownership.
• Employees: Reflects participation in the company's Employee Stock Purchase Plan, a common benefit.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction where the Chief Medical Officer disposed of a small number of shares likely for tax withholding, while simultaneously increasing overall beneficial ownership through an Employee Stock Purchase Plan. Such a transaction is not typically a strong signal for a 'buy' or 'sell' recommendation, as it reflects standard compensation and tax management rather than a significant change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific insider filing.

Keywords

Avalo Therapeutics, AVTX, Form 4, Insider Transaction, Mittie Doyle, Chief Medical Officer, Common Stock, Employee Stock Purchase Plan, Beneficial Ownership